Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aimee Jackson

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
Nature Communications|November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysisZijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
Nature Communications|November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysisZijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.
Pageof 3